198 related articles for article (PubMed ID: 18325618)
21. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
22. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
23. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
[TBL] [Abstract][Full Text] [Related]
24. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
25. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
26. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
27. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
28. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma.
Říhová B; Etrych T; Šírová M; Tomala J; Ulbrich K; Kovář M
J Drug Target; 2011 Dec; 19(10):890-9. PubMed ID: 21981636
[TBL] [Abstract][Full Text] [Related]
31. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
32. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.
Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M
Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555
[TBL] [Abstract][Full Text] [Related]
33. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
[TBL] [Abstract][Full Text] [Related]
34. Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia.
Pola R; Laga R; Ulbrich K; Sieglová I; Král V; Fábry M; Kabešová M; Kovář M; Pechar M
Biomacromolecules; 2013 Mar; 14(3):881-9. PubMed ID: 23373696
[TBL] [Abstract][Full Text] [Related]
35. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
36. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
37. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
[TBL] [Abstract][Full Text] [Related]
38. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
39. Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.
Demoy M; Minko T; Kopecková P; Kopecek J
J Control Release; 2000 Oct; 69(1):185-96. PubMed ID: 11018556
[TBL] [Abstract][Full Text] [Related]
40. Induction of systemic antitumour resistance with targeted polymers.
Rihova B; Strohalm J; Kovar M; Mrkvan T; Subr V; Hovorka O; Sirova M; Rozprimova L; Kubackova K; Ulbrich K
Scand J Immunol; 2005 Jul; 62 Suppl 1():100-5. PubMed ID: 15953192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
